What is the primary purpose of these agreements for Exelon?

These agreements indicate Exelon's strategy to raise substantial capital. The Forward Sale Agreements, combined with the underwriting of common stock, suggest a plan to sell equity and receive proceeds, while the Equity Units offering aims to raise debt-like capital.

When will Exelon receive the proceeds from the forward sale agreements?

Exelon expects to receive proceeds from the forward sale agreements upon full physical settlement, which is anticipated around October 29, 2015. However, the settlement date can be accelerated by either Exelon or the forward purchasers under specific conditions outlined in the agreements.

What are Equity Units and why did Exelon issue them?

Equity Units are complex financial instruments that typically combine debt and equity features. The issuance of $1.0 billion in Equity Units suggests Exelon was seeking diverse funding sources, potentially to finance operations, capital expenditures, or corporate actions like acquisitions.

What are the risks associated with the forward sale agreements for Exelon?

Key risks include potential market disruption events, changes in borrowing costs for the forward purchasers, regulatory changes, or corporate events (like dividends or mergers) that could trigger acceleration clauses and affect settlement terms. The company's financial health and stock performance also play a role.

EXC 8-K: Material Agreements

Summary

Exelon Corporation (EXC) filed an 8-K on June 17, 2014, detailing material definitive agreements related to significant equity offerings. The company entered into Forward Sale Agreements with Barclays Bank PLC and Goldman, Sachs & Co. for an aggregate of 57,500,000 shares of common stock. These agreements are tied to an underwriting agreement for the sale of these shares at $33.95 per share, with settlement anticipated around October 29, 2015, though acceleration clauses exist for both parties under certain conditions. Additionally, Exelon executed an underwriting agreement for the public offering and sale of 20,000,000 Equity Units, representing an aggregate principal amount of $1.0 billion. Options were exercised for an additional 3,000,000 Equity Units. These transactions suggest Exelon was actively managing its capital structure and seeking to raise substantial funds through both equity and debt-like instruments during this period.

Key Highlights

1Exelon entered into Forward Sale Agreements for 57,500,000 shares of common stock with Barclays Bank PLC and Goldman, Sachs & Co.
2These forward sales are linked to an underwriting agreement to sell the shares at $33.95 per share.
3The expected settlement date for the forward sale agreements is October 29, 2015, subject to potential acceleration.
4Exelon also entered into an underwriting agreement for the sale of 20,000,000 Equity Units, totaling $1.0 billion.
5Underwriters exercised their option to purchase an additional 7,500,000 shares of common stock and 3,000,000 Equity Units.
6The company may elect cash or net share settlement for the forward sale agreements, impacting future share count and cash flow.
7The filing includes legal opinions regarding the common stock and equity units offerings.

EXELON CORP 8-K Report, Material Agreement (Jun 17, 2014)

Summary

Key Highlights

Frequently Asked Questions